Biomarker Research in ADHD: the Impact of Nutrition
BRAIN
1 other identifier
interventional
100
1 country
1
Brief Summary
Attention deficit hyperactivity disorder (ADHD) is the most common childhood behavioural disorder, causing significant impediment to a child's development. The exact aetiology of ADHD is still unknown. It is a complex disorder with numerous contributing (epi)genetic and environmental factors. Currently, treatment predominantly consists of behavioural and pharmacological therapy. However, medication use is associated with several side effects and concerns about long-term effects and efficacy exist. Therefore, there is considerable interest in the development of alternative treatment options. Double-blind research investigating the effect of a few-foods diet (FFD) has demonstrated large improvements in ADHD symptoms. However, following an FFD requires great effort of both the child and parents. To make this treatment easier or potentially obsolete, it is important to understand how and in which children an FFD affects ADHD symptoms. The investigators hypothesise that an FFD affects brain function and behaviour, including ADHD symptoms, via the complex network of communication between the microbiota, gut and brain, i.e. the MGB axis. The aim of this study is to identify potential mechanism(s) underlying the impact of an FFD on ADHD symptoms and to identify biomarkers that predict the response to the FFD. 100 boys with ADHD will follow the FFD for 5 weeks. After inclusion, all participants will start with a baseline period, during which they will maintain their regular diet. The baseline period ends at the end of week 2. Thereafter, participants will follow a 5-week FFD, preceded by a 1-week transition period. The FFD period ends at the end of week 8. At the end of the baseline period (i.e. at the end of week 2) and at the end of the FFD (i.e. at the end of week 8), fMRI scans will be made, blood and buccal saliva will be collected, and stool and urine will be handed in. Children will do computer tasks and parents will complete questionnaires to monitor ADHD and physical complaints. All samples will be analysed by researchers blinded to behavioural responses to the FFD. To assess the impact of the FFD on brain function and the MGB axis, associations between ADHD behavioural changes and changes in other primary and secondary study outcomes will be analysed. This study may lead to the identification of biomarkers that can predict the response to an FFD. Understanding which changes - induced by an FFD - lead to improvements in ADHD symptoms may provide new avenues for developing treatments. Ultimately, the findings may enable personalised intervention strategies based on an individuals' configuration of the MGB axis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 19, 2018
CompletedStudy Start
First participant enrolled
February 19, 2018
CompletedFirst Posted
Study publicly available on registry
February 22, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 21, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 21, 2019
CompletedJuly 1, 2019
June 1, 2019
1.3 years
January 19, 2018
June 28, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change in neural activation patterns during execution of tasks
Using fMRI, blood oxygen-level-dependent (BOLD) signal changes will be measured whilst performing cognitive tasks that assess inhibitory control and selective attention, i.e. a stop-signal task (response inhibition) and a Flanker task (response conflict and associated error monitoring). fMRI BOLD responses will be assessed between variable task-elements and performance. Region of interest (ROI; anatomically defined regions in the brain) analyses of the BOLD responses will be performed.
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in peripheral blood metabolite concentrations
Global metabolite profiles will be examined in plasma (or alternatively serum) obtained from whole blood using mass-spectrometry profiling. Phenylalanine and tyrosine plasma levels represent primary outcomes.
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in functional composition of the gut microbiota
Metagenome profiling will be performed on stool samples, leveraging Illumina next-generation sequencing technology. Sequence read data will be used for abundance profiling of microbiota genes that encode enzymes directly involved in the production or degradation of the dopamine and noradrenaline precursors phenylalanine and tyrosine.
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in ADHD symptom scores
ADHD symptoms will be scored using the 18-item ADHD rating scale, which is based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV and consists of 9 items that assess inattention and 9 items that focus on hyperactivity and impulsivity.
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Secondary Outcomes (15)
Change in whole brain neural activation patterns during the execution of tasks
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in whole brain functional connectivity at rest
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in taxonomic and functional composition of the gut microbiota
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in metabolite profiles
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
Change in peripheral blood cell gene expression profiles
Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)
- +10 more secondary outcomes
Other Outcomes (2)
IQ-score
At the screening session, prior to inclusion of participant in the study
Change in taxonomic and functional composition of the gut microbiota
Prior to the screening (i.e. week 0) and after the baseline period (i.e. at the end of week 2)
Study Arms (1)
Few-foods diet intervention
EXPERIMENTALInterventions
The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
Eligibility Criteria
You may qualify if:
- Meeting DSM-IV ADHD criteria
- Male
- Aged 8 up to and including 10 years
- Right-handed
- Available to visit Wageningen University for 4 sessions (i.e. intake, screening, T1 and T2), of which 3 sessions including the child (screening, T1, T2)
- Upon study start, fully understanding and agreeing to the study objectives and having dated and signed an informed consent to participate in the study, including permission that material will be used or archived for (epi)genetic testing
- Willing to be informed about chance-findings that may have implications for the health of the child or his family, and approving of reporting this to the child's medical specialist or family's general physician.
- If the child uses "over the counter" medication, e.g. laxatives, melatonin for sleeping problems or hay fever medication, parents are asked to share the information leaflet, and if necessary participants are asked to change to alternatives that are free of additives that may affect ADHD, e.g. laxatives free of artificial sweeteners, sugar and cacao.
You may not qualify if:
- Diagnosis Autism Spectrum Disorder
- Diagnosis Developmental Coordination Disorder
- Premature birth (\< 36 weeks) and/or oxygen deprivation during birth
- Diagnosed chronic gastrointestinal disorder, i.e. inflammatory bowel disease, irritable bowel syndrome, celiac disease, non-celiac gluten-intolerance (gluten-sensitivity) or lactose-intolerance
- Auto-immune disorder (e.g. diabetes mellitus type 1)
- Vegetarian/vegan
- Diagnosis dyslexia and/or dyscalculia
- IQ \< 85
- Following behavioural therapy
- Use of ADHD medication
- Use of systemic antibiotics, antifungals, antivirals or antiparasitics in the past six months
- Insufficient command of the Dutch language by either parents or child that may affect understanding and execution of study and dietary instructions
- Family circumstances that may compromise following or completion of the diet, including but not limited to family relational problems
- Having a contra-indication to MRI scanning (including, but not limited to): pacemakers and defibrillators, intraorbital or intraocular metallic fragments, ferromagnetic implants, claustrophobia.
- Two weeks prior to the start of the study, dietary supplements (e.g. antioxidants, minerals, vitamins) or pro- or prebiotics use has to be stopped.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wageningen Universitylead
- ADHD Research Centrecollaborator
Study Sites (1)
Wageningen University
Wageningen, Netherlands
Related Publications (3)
Pelsser LM, Frankena K, Toorman J, Savelkoul HF, Dubois AE, Pereira RR, Haagen TA, Rommelse NN, Buitelaar JK. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011 Feb 5;377(9764):494-503. doi: 10.1016/S0140-6736(10)62227-1.
PMID: 21296237BACKGROUNDPelsser LM, Frankena K, Toorman J, Rodrigues Pereira R. Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD. PLoS One. 2017 Jan 25;12(1):e0169277. doi: 10.1371/journal.pone.0169277. eCollection 2017.
PMID: 28121994BACKGROUNDStobernack T, de Vries SPW, Rodrigues Pereira R, Pelsser LM, Ter Braak CJF, Aarts E, van Baarlen P, Kleerebezem M, Frankena K, Hontelez S. Biomarker Research in ADHD: the Impact of Nutrition (BRAIN) - study protocol of an open-label trial to investigate the mechanisms underlying the effects of a few-foods diet on ADHD symptoms in children. BMJ Open. 2019 Nov 5;9(11):e029422. doi: 10.1136/bmjopen-2019-029422.
PMID: 31694844DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michiel Kleerebezem, Prof. dr.
Wageningen University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2018
First Posted
February 22, 2018
Study Start
February 19, 2018
Primary Completion
June 21, 2019
Study Completion
June 21, 2019
Last Updated
July 1, 2019
Record last verified: 2019-06
Data Sharing
- IPD Sharing
- Will not share